Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock ...

Zoetis Inc. closed 23.70% below its 52-week high of $200.33, which the company reached on September 19th.

The stock's fall snapped a three-day winning streak.

Each stock has a return on invested capital between 17% and 27%, showing a strong ability to reinvest in their businesses ...

Review quarterly and annual revenue, net income, and cash flow for Zoetis Inc Class A (ZTS:XNYS) stock through the last fiscal year.

Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...

Zoetis delivered revenue and adjusted EPS above Wall Street expectations in Q1, driven by strong organic operational growth across its diverse portfolio. Management pointed to particularly robust ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

Animal health company Zoetis (NYSE:ZTS) in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, the company’s full-year revenue guidance of $9.3 billion at the ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

U.S. equities rose at midday ahead of the latest announcement from the Federal Reserve, as President Donald Trump again ...

Zoetis published its 2024 Sustainability Progress Update" Advancing Sustainability in Animal Health for a Better Future" to highlight the company’ s continued progress toward achieving its ...